Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD97
belongs to the adhesion GPCR family characterized by a long ECD linked to the 7TM via a GPCR proteolytic site (GPS) and plays important roles in modulating cell migration and invasion.
CD97
(EGF1-5) is a splicing variant of
CD97
that recognizes a specific ligand chondroitin sulfate on cell membranes and the extracellular matrix. The aim of this study was to elucidate the extracellular molecular basis of the
CD97
EGF1-5 isoform in protein expression, auto-proteolysis and cell adhesion, including epidermal growth factor (EGF)-like domain, GPCR autoproteolysis-inducing (GAIN) domain, as well as GPS mutagenesis and N-glycosylation. Both wild-type (WT)
CD97
-ECD and its truncated, GPS mutated,
PNGase F
-deglycosylated, and N-glycosylation site mutated forms were expressed and purified. The auto-proteolysis of the proteins was analyzed with Western blotting and SDS-PAGE. Small angle X-ray scattering (SAXS) and molecular modeling were used to determine a structural profile of the properly expressed receptor. Potential N-glycosylation sites were identified using MS and were modulated with
PNGase F
digestion and glyco-site mutations. A flow cytometry-based HeLa cell attachment assay was used for all aforementioned
CD97
variants to elucidate the molecular basis of
CD97
-HeLa interactions. A unique concentration-dependent GPS auto-proteolysis was observed in
CD97
EGF1-5 isoform with the highest concentration (4 mg/mL) per sample was self-cleaved much faster than the lower concentration (0.1 mg/mL), supporting an intermolecular mechanism of auto-proteolysis that is distinct to the reported intramolecular mechanism for other
CD97
isoforms. N-glycosylation affected the auto-proteolysis of
CD97
EGF1-5 isoform in a similar way as the other previously reported
CD97
isoforms. SAXS data for WT and deglycosylated CD97ECD revealed a spatula-like shape with GAIN and EGF domains constituting the body and handle, respectively. Structural modeling indicated a potential interaction between the GAIN and EGF5 domains accounting for the absence of expression of the GAIN domain itself, although EGF5-GAIN was expressed similarly in the wild-type protein. For HeLa cell adhesion, the GAIN-truncated forms showed dramatically reduced binding affinity. The
PNGase F
-deglycosylated and GPS mutated forms also exhibited reduced HeLa attachment compared with WT
CD97
. However, neither N-glycosylation mutagenesis nor auto-proteolysis inhibition caused by N-glycosylation mutagenesis affected
CD97
-HeLa cell interactions. A comparison of the HeLa binding affinities of
PNGase F
-digested, GPS-mutated and N-glycosylation-mutated
CD97
samples revealed diverse findings, suggesting that the functions of
CD97
ECD were complex, and various technologies for function validation should be utilized to avoid single-approach bias when investigating N-glycosylation and auto-proteolysis of
CD97
. A unique mechanism of concentration-dependent auto-proteolysis of the
CD97
EGF1-5 isoform was characterized, suggesting an intermolecular mechanism that is distinct from that of other previously reported
CD97
isoforms. The EGF5 and GAIN domains are likely associated with each other as
CD97
expression and SAXS data revealed a potential interaction between the two domains. Finally, the GAIN and EGF domains are also important for
CD97
-HeLa adhesion, whereas N-glycosylation of the
CD97
GAIN domain and GPS auto-proteolysis are not required for HeLa cell attachment.
...
PMID:Biochemical features of the adhesion G protein-coupled receptor CD97 related to its auto-proteolysis and HeLa cell attachment activities. 2764 34